Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab or talquetamab combinations versus DRd in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON59441Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of teclistamab, talquetamab, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and 12-month minimal residual disease-negative complete response. Started Oct 2022; status: active, not recruiting.
02
Drugs
teclistamabtalquetamabdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59441.